Company Overview and News
KUALA LUMPUR, Sept 21 — Shares on Bursa Malaysia remained in positive territory at mid-morning, supported by persistent buying in selected heavyweights and buoyed by optimism over a possible lenient outcome on the US-China trade negotiations.
PBLOF 0026 1295 BSMAF 1818
KUALA LUMPUR, Sept 21 — Shares on Bursa Malaysia were on a positive momentum in early trading today, in line with overnight gains in most Asian markets, buoyed by optimism over a possible lenient outcome on the US-China trade negotiations.
PBLOF 1295 BSMAF 1818
KUALA LUMPUR: K-Star Sports Ltd saw a 24.98% stake or 95.15 million of its shares traded off-market yesterday, at a three sen per share premium to its last price in the open market.
5172 BSMAF 1818
KUALA LUMPUR (Sept 20): Eco World Development Group Bhd (EcoWorld) saw its net profit jump 47.6% to RM38.52 million in the third financial quarter ended July 31, 2018 (3QFY18) from RM26.09 million a year ago, on higher profit contribution from projects undertaken by its joint ventures (JVs).
8206 BSMAF 1818
KUALA LUMPUR (Sept 20): Selangor Properties Bhd's net profit surged 70.2% to RM33.2 million in the third financial quarter ended July 31, 2018 (3QFY18) from RM19.51 million a year ago, mainly due to higher foreign exchange (forex) gain of RM16.3 million.
1783 SGPBY BSMAF 1818
KUALA LUMPUR (Sept 20): Shares of Pinehill Pacific Bhd will be suspended from trading with effect from 9am tomorrow (Friday, Sept 21) pending the release of a material announcement, the palm oil player said in a filing with Bursa Malaysia today.
1902 BSMAF 1818
KUALA LUMPUR (Sept 20): AWC Bhd has filed a lawsuit against BUCG (M) Sdn Bhd for failing to settle RM2.06 million in outstanding payment for subcontract works of a project developing one block of serviced apartments and a 55-storey hotel at Jalan Conlay here.
KUALA LUMPUR (Sep 20): Eco World International Bhd (EWI) has eked out its first quarterly profit since listing in 2015 amid a pick-up in property sales which has put the property developer on-track to achieving its target of RM3 billion sales in the current financial year.
KUALA LUMPUR: The trading of shares in Pinehill Pacific Bhd (PinePac) will be suspended on Friday to make way for a material announcement, the company said in a filing with Bursa Malaysia.
1902 BSMAF 1818
KUALA LUMPUR (Sept 20): Tin miner and metal producer Malaysia Smelting Corp Bhd (MSC) is leasing two pieces of land totalling 423 acres in Klian Intan, Perak owned by Menteri Besar Inc (Perak) (MB Inc) for dumping overburden, tailings and slime arising from ongoing tin mining activities at its open-pit tin mine.
KUALA LUMPUR, Sept 20 — Bursa Malaysia ended higher for the second consecutive day today on continued buying interest in selected heavyweights and finance counters, and in line with most regional bourses, dealers said.
PBLOF 7036 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR (Sept 20): Scientex Bhd reported a 22% rise in its fourth quarter net profit at RM88.29 million, from RM72.13 million a year earlier, as revenue increased on better sales from its manufacturing division. Scientex's manufacturing division includes stretch film production.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...